Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy. | Synapse
March 10, 2026
Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.
Key Points
The aim is to evaluate the safety and efficacy of belumosudil in patients with chronic graft-versus-host disease after multiple therapies.
Real-world experience analysis of heavily treated patients
Assessment of cGVHD severity
Monitoring safety and efficacy profiles
Belumosudil demonstrated a favorable safety profile
Efficacy was confirmed in patients who had undergone two or more treatments
Most patients had severe cGVHD symptoms but responded positively
Abstract
. Our real-world experience, involving heavily pretreated patients with predominantly severe cGVHD, confirms the safety and efficacy profile of belumosudil.